# US 2016/0250328 A1 · Combination therapy for treating her2-positive cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250328 A1
- Document ID: US20160250328A1
- Status: Published application
- Kind: A1
- Application number: 14/650,250
- Filed: 2013-12-03
- Published: 2016-09-01
- Earliest claimed: 2012-12-03
- Assignees: Merrimack Pharmaceuticals, Inc.
- Applicants: Merrimack Pharmaceuticals, Inc.
- Inventors: Victor Moyo; Bart S. Hendriks; Thomas Wickham; Elena Geretti; Joseph G. Reynolds; Christopher W. Espelin
- Web page: https://patentgrep.com/patent/US20160250328A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61J 1/16: Holders for containers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- C07K 16/40: against enzymes
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of treating a patient with breast cancer that overexpresses HER2, the method comprising administering to the patient, a HER2 directed therapy consisting of: an initial dose of 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes and 8 mg/kg trastuzumab, followed by the administration to the patient once every three weeks of 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in the MM302 doxorubicin HER-2 targeted immunoliposomes and 6 mg/kg trastuzumab, to treat the breast cancer.

### Claim 30 (depends on 29)

The method of claim 29, wherein the breast cancer is a locally advanced/unresectable or metastatic advanced breast cancer.

### Claim 31 (depends on 29)

The method of claim 29, wherein the breast cancer characterized by overexpression of HER2 receptor is further characterized as being HER2 2+, HER2 3+, or HER2 FISH positive.

### Claim 32 (depends on 29)

The method of claim 29, wherein the breast cancer characterized by overexpression of HER2 receptor is further characterized as expressing an average of at least 200,000 cell surface HER2 receptors per cell.

### Claim 33 (depends on 29)

The method of claim 29, wherein the cumulative concentration of doxorubicin administered to the patient in the HER-2 targeted immunoliposomes is less than 550 mg/m2 (doxorubicin-HCl equivalent).

### Claim 34 (depends on 29)

The method of claim 29, wherein the MM302 doxorubicin HER-2 targeted immunoliposomes are administered intravenously over 60 minutes.

### Claim 35 (depends on 29)

The method of claim 29, wherein the MM302 doxorubicin HER-2 targeted immunoliposomes are administered before the trastuzumab.

### Claim 36 (depends on 29)

The method of claim 29, further comprising one or more of the following:
a. the breast cancer is a locally advanced/unresectable breast cancer;
b. the breast cancer is a metastatic advanced breast cancer;
c. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 2+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
d. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 3+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
e. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 FISH positive prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
f. the breast cancer characterized by overexpression of HER2 receptor is further characterized as expressing an average of at least 200,000 cell surface HER2 receptors per cell;
g. the cumulative concentration of doxorubicin administered to the patient in the HER-2 targeted immunoliposomes is less than 550 mg/m2 (doxorubicin-HCl equivalent);
h. the MM302 doxorubicin HER-2 targeted immunoliposomes are administered intravenously over 60 minutes; and
i. the MM302 doxorubicin HER-2 targeted immunoliposome are administered before the trastuzumab.

### Claim 37

A method of treating a patient susceptible to or diagnosed with locally advanced/unresectable breast cancer or metastatic advanced breast cancer having a HER2 immunohistochemistry (IHC) score of HER2 2+ or HER2 3+, the method comprising administering to the patient:
a. 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 8 mg/kg trastuzumab, followed by
b. administering to the patient once every three weeks 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 6 mg/kg trastuzumab, to treat the locally advanced/unresectable or metastatic advanced breast cancer.

### Claim 38 (depends on 37)

The method of claim 37, wherein the locally advanced/unresectable breast cancer or metastatic advanced breast cancer characterized by overexpression of HER2 receptor is further characterized as being HER2 FISH positive.

### Claim 39 (depends on 37)

The method of claim 37, wherein the locally advanced/unresectable breast cancer or metastatic advanced breast cancer characterized by overexpression of HER2 receptor is further characterized as expressing an average of at least 200,000 cell surface HER2 receptors per cell.

### Claim 40 (depends on 37)

The method of claim 37, wherein the cumulative concentration of doxorubicin administered to the patient in the HER-2 targeted immunoliposomes is less than 550 mg/m2 (doxorubicin-HCl equivalent).

### Claim 41 (depends on 37)

The method of claim 37, wherein the MM302 doxorubicin HER-2 targeted immunoliposomes are administered intravenously over 60 minutes.

### Claim 42 (depends on 37)

The method of claim 37, further comprising one or more of the following:
a. the breast cancer is a locally advanced/unresectable breast cancer;
b. the breast cancer is a metastatic advanced breast cancer;
c. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 2+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
d. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 3+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
e. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 FISH positive prior to administering the MM302 doxorubicin HER-2 targeted immunoliposomes;
f. the breast cancer characterized by expression of HER2 receptor further characterized as expressing an average of at least 200,000 cell surface HER2 receptors per cell;
g. the cumulative concentration of doxorubicin administered to the patient in the HER-2 targeted immunoliposomes is less than 550 mg/m2 (doxorubicin-HCl equivalent);
h. the MM302 doxorubicin HER-2 targeted immunoliposomes are administered intravenously over 60 minutes; and
i. the MM302 doxorubicin HER-2 targeted immunoliposomes are administered before the trastuzumab.

### Claim 43

A method of treating a patient susceptible to or diagnosed with locally advanced/unresectable breast cancer or metastatic advanced breast cancer characterized as being HER2 FISH positive, the method comprising administering to the patient:
a. 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 8 mg/kg trastuzumab, followed by
b. administering to the patient once every three weeks 30 mg/m2 (doxorubicin-HCl equivalent) of doxorubicin in MM302 doxorubicin HER-2 targeted immunoliposomes in combination with 6 mg/kg trastuzumab, to treat the locally advanced/unresectable or metastatic advanced breast cancer.

### Claim 44 (depends on 43)

The method of claim 43, wherein the locally advanced/unresectable or metastatic advanced breast cancer characterized as being HER2 FISH positive is further characterized by a HER2 immunohistochemistry (IHC) score of HER2 2+ or HER2 3+ prior to administration of the MM302 doxorubicin HER-2 targeted immunoliposomes.

### Claim 45 (depends on 43)

The method of claim 43, wherein the locally advanced/unresectable breast cancer or metastatic advanced breast cancer characterized as being HER2 FISH positive expresses an average of at least 200,000 cell surface HER2 receptors per cell.

### Claim 46 (depends on 43)

The method of claim 43, wherein the cumulative concentration of doxorubicin administered to the patient in the MM302 doxorubicin HER-2 targeted immunoliposomes is less than 550 mg/m2 (doxorubicin-HCl equivalent).

### Claim 47 (depends on 43)

The method of claim 43, wherein the MM302 doxorubicin HER-2 targeted immunoliposomes are administered intravenously over 60 minutes.

### Claim 48 (depends on 43)

The method of claim 43, wherein the locally advanced/unresectable breast cancer is characterized by a HER2 immunohistochemistry (IHC) score of HER2 2+ or HER2 3+ prior to administration of the MM302 doxorubicin HER-2 targeted immunoliposomes, and wherein the cumulative concentration of doxorubicin in the HER-2 targeted immunoliposomes administered to the patient is less than 550 mg/m2 (doxorubicin-HCl equivalent).

### Claim 49 (depends on 48)

The method of claim 48, wherein the locally advanced/unresectable breast cancer is characterized by a HER2 immunohistochemistry (IHC) score of HER2 3+ prior to administration of the MM302 doxorubicin HER-2 targeted immunoliposome.

### Claim 50 (depends on 43)

The method of claim 43, wherein the metastatic advanced breast cancer is characterized by a HER2 immunohistochemistry (IHC) score of HER2 2+ or HER2 3+ prior to administration of the MM302 doxorubicin HER-2 targeted immunoliposomes, and wherein the cumulative concentration of doxorubicin in the HER-2 targeted immunoliposomes administered to the patient is less than 550 mg/m2 (doxorubicin-HCl equivalent).

### Claim 51 (depends on 50)

The method of claim 50, wherein the metastatic advanced breast cancer is characterized by a HER2 immunohistochemistry (IHC) score of HER2 3+ prior to administration of the MM302 doxorubicin HER-2 targeted immunoliposomes.

### Claim 52 (depends on 43)

The method of claim 43, further comprising one or more of the following:
a. the breast cancer is a locally advanced/unresectable breast cancer;
b. the breast cancer is a metastatic advanced breast cancer;
c. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 2+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposome;
d. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 3+ prior to administering the MM302 doxorubicin HER-2 targeted immunoliposome;
e. the breast cancer characterized by expression of HER2 receptor is further characterized as being HER2 FISH positive prior to administering the MM302 doxorubicin HER-2 targeted immunoliposome;
f. the breast cancer characterized by expression of HER2 receptor further characterized as expressing an average of at least 200,000 cell surface HER2 receptors per cell;
g. the cumulative concentration of doxorubicin administered to the patient in the HER-2 targeted immunoliposome is less than 550 mg/m2 (doxorubicin-HCl equivalent);
h. the MM302 doxorubicin HER-2 targeted immunoliposome is administered intravenously over 60 minutes; and
i. the MM302 doxorubicin HER-2 targeted immunoliposome is administered before the trastuzumab.
